Skye Bioscience, Inc. (SKYE)
- Previous Close
1.8550 - Open
1.8600 - Bid 1.7800 x 200
- Ask 1.8500 x 200
- Day's Range
1.7800 - 1.9000 - 52 Week Range
1.1400 - 13.4400 - Volume
162,704 - Avg. Volume
696,421 - Market Cap (intraday)
56.374M - Beta (5Y Monthly) 1.75
- PE Ratio (TTM)
-- - EPS (TTM)
-0.7300 - Earnings Date May 8, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
16.21
Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.
skyebioscience.comRecent News: SKYE
View MorePerformance Overview: SKYE
Trailing total returns as of 5/7/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SKYE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SKYE
View MoreValuation Measures
Market Cap
56.37M
Enterprise Value
-11.59M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.83
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-44.56%
Return on Equity (ttm)
-80.48%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-26.57M
Diluted EPS (ttm)
-0.7300
Balance Sheet and Cash Flow
Total Cash (mrq)
68.42M
Total Debt/Equity (mrq)
0.67%
Levered Free Cash Flow (ttm)
-9.05M